SM
CLVS

SG3 Management’s Clovis Oncology, Inc. CLVS Stock Holding History

SG3 Management’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-5,000
Closed -$14K – 1484
2021
Q4 		$14K Hold
5,000
– – ﹤0.01% 1000
2021
Q3 		$22K Hold
5,000
– – ﹤0.01% 936
2021
Q2 		$29K Hold
5,000
– – ﹤0.01% 959
2021
Q1 		$35K Buy
+5,000
New +$33.5K ﹤0.01% 1106

Other funds holding CLVS

N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

SG3 Management's CLVS Position: Q3 2020 in Review

SG3 Management sold out of Clovis Oncology, Inc. (CLVS) in Q3 2020, closing a stake of 5,500 shares — an estimated $37K sold.

SG3 Management first reported a position in CLVS in Q1 2020 and held it in 2 quarters. The position peaked at $64K in Q1 2020. 169 funds tracked by Wall St. Rank hold CLVS as of Q3 2020.

  • SG3 Management reported no remaining Clovis Oncology, Inc. position as of Q3 2020 after selling out during the quarter.
  • SG3 Management sold 5,500 Clovis Oncology, Inc. shares in Q3 2020, an estimated $37K.
  • SG3 Management first reported a position in Clovis Oncology, Inc. in Q1 2020 and held it in 2 quarters.
  • SG3 Management's Clovis Oncology, Inc. position peaked at $64K in Q1 2020.
  • 169 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2020.

Based on SG3 Management's 13F filing for Q3 2020, filed 13 Nov 2020.